Silk Road Medical Enhances TCAR Portfolio with Launch of ENROUTE Transcarotid Neuroprotection System PLUS
SUNNYVALE, Calif. April 02, 2024 - Silk Road Medical, Inc. (Nasdaq: SILK), a leading company dedicated to reducing the risk of stroke and its detrimental consequences, has recently unveiled its latest innovation, the ENROUTE Transcarotid Neuroprotection System PLUS (NPS PLUS). The introduction of this advanced device adds significant enhancements to Silk Road Medical’s TCAR portfolio, ensuring smoother arterial sheath insertion, improved flow precision, and a simplified preparation process for surgical teams. Most importantly, it guarantees unmatched neuroprotection during the TCAR procedure.
TCAR (Transcarotid Artery Revascularization) has become a preferred method for preventing stroke in patients with carotid artery disease. This minimally invasive procedure involves the insertion of a stent through a small incision in the neck. During the procedure, blood flow is temporarily reversed, diverting potential debris away from the brain. Previously, Silk Road Medical introduced the ENROUTE Transcarotid Neuroprotection System, which significantly improved neuroprotection during TCAR. The launch of the ENROUTE Transcarotid Neuroprotection System PLUS builds upon that success, taking patient safety and efficiency to new heights.
The NPS PLUS device distinguishes itself through various key features. Firstly, it ensures smoother arterial sheath insertion, facilitating the entire TCAR procedure. Secondly, the device offers greater flow precision, enabling surgeons to achieve enhanced precision and accuracy during stent placement. This feature can greatly contribute to better patient outcomes and minimized risks. Lastly, the NPS PLUS offers a simplified prep experience for surgical teams, streamlining the pre-operative process and potentially reducing operation time.
Silk Road Medical’s commitment to unparalleled neuroprotection is reflected in the innovative design of the ENROUTE Transcarotid Neuroprotection System PLUS. By leveraging technological advancements, the company aims to improve the overall patient experience and outcomes.
Stroke is a leading cause of death and disability worldwide, making stroke prevention a critical healthcare goal. Silk Road Medical’s continuous efforts to enhance its TCAR portfolio demonstrate the company’s dedication to improving patient care and reducing the burden of stroke.
In conclusion, the launch of Silk Road Medical’s ENROUTE Transcarotid Neuroprotection System PLUS signifies a significant development in the field of stroke prevention. This cutting-edge technology provides smoother insertion, improved flow precision, and a simplified preparation process for surgical teams. With its unwavering focus on neuroprotection, Silk Road Medical is at the forefront of stroke prevention, revolutionizing TCAR procedures and paving the way for better patient outcomes.
Comments